Freespira Launches Fifth-Generation At-Home Anxiety Treatment Device
Published: 11 Feb 2026
Author: Precedence Research
Freespira is the developer of the first FDA-cleared, at-home medical device for treating anxiety disorders such as panic disorder and post-traumatic stress disorder (PTSD). The company introduced Freespira Sensor Technology v5 (FST5), its most advanced platform to date. The fifth-generation system is also a significant design development in its ability to integrate sensors and display in one fully integrated user-friendly unit.
Compared to the conventional anxiety treatments that were highly dependent on medication or psychotherapy, the treatment effect of Freespira focuses on the physiological causes of the anxiety symptoms. The system is based on real-time, computer-assisted breath exercise with one-on-one video coaching to correct dysfunctional breathing patterns that are usually related to panic and PTSD.
The device monitors the respiratory rate and carbon dioxide (CO2) concentration in the end-tidal by directly measuring it. This assists patients in training their respiratory system to stabilize their nervous system. FST5 launch is not merely the updating of hardware, but a strategic expansion to make clinically approved, medication-free mental health care more accessible.
Due to the steady increase in mental health disorders in the world, the need to find a scalable, evidence-based, and medication-free solution to them is growing. A large percentage of patients do not react to pharmaceuticals properly, or they favor methods that do not involve taking drugs on a long-term basis. The device of Freespira, which works on an evaluation of respiratory peculiarities, closes this gap, concentrating not only on the subjective complaint but on quantifiable physiological indicators. Furthermore, the release of FST5 makes Freespira the next-generation mental health technology, such as precision monitoring and behavioral intervention intersect to provide quantifiable results.
Executives’ Statements
Joe Perekupka, CEO of Freespira, stated: “The launch of the FST5 reflects our commitment to continually improving the user experience, which ultimately improves patient adherence. By enhancing connectivity and simplifying device design, we are expanding access to communities that have historically faced barriers to reliable internet and consistent care.”
Simon Thomas, President of Freespira, added: “By integrating the sensor and display into one device and expanding connectivity options, we are making it easier than ever for patients to engage with our treatment, without sacrificing the clinical precision providers and patients expect.”